SEC Tracker
Get the app

PAVmed PAVM

PAVmed Q3 FY24: revenue $1.0M; diluted EPS $1.44

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers PAVmed reported for Q3 FY24, the quarter ended Sep 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$1.0MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income$64.4MAgainst −$17.7M in Q3 FY2310-Q income statement, on EDGAR
  3. Diluted EPS$1.44Against −$0.16 in Q3 FY2310-Q income statement, on EDGAR
  4. Cash and cash equivalents$765K−97% from $26.4M in Q3 FY2310-Q balance sheet, on EDGAR
  5. Cash from operations−$8.9MAgainst −$11.1M in Q3 FY2310-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when PAVmed files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (3841) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Intelligent Bio Solutions INBS public float $12M, Dec 31, 2025
  2. PetVivo Holdings PETV public float $12M, Jun 29, 2026
  3. Lyra Therapeutics LYRA public float $11M, Jun 30, 2025
  4. Nexgel NXGL public float $11M, Jun 30, 2025
  5. Mountain Crest Acquisition Corp. V MCAG public float $10M, Jun 30, 2025